$-0.21 EPS Expected for Histogenics Corporation (HSGX)

July 14, 2018 - By Rene Reddy

Histogenics Corporation (NASDAQ:HSGX) Logo

Analysts expect Histogenics Corporation (NASDAQ:HSGX) to report $-0.21 EPS on August, 9.They anticipate $0.04 EPS change or 16.00 % from last quarter’s $-0.25 EPS. After having $-0.20 EPS previously, Histogenics Corporation’s analysts see 5.00 % EPS growth. The stock decreased 0.80% or $0.02 during the last trading session, reaching $2.49. About 33,177 shares traded. Histogenics Corporation (NASDAQ:HSGX) has risen 41.82% since July 14, 2017 and is uptrending. It has outperformed by 29.25% the S&P500.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company has market cap of $71.43 million. The firm offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It currently has negative earnings. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.

Histogenics Corporation (NASDAQ:HSGX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.